Welcome to our dedicated page for Abbvie SEC filings (Ticker: ABBV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
With operations spanning immunology, oncology, neuroscience, aesthetics, and eye care, AbbVie SEC filings reveal how one of biopharma largest companies allocates resources across its therapeutic divisions. Each quarterly 10-Q breaks down revenue by segment, showing which areas drive growth and which face competitive pressure from biosimilars and new market entrants.
AbbVie 10-K annual reports detail the company drug development pipeline, including clinical trial phases, anticipated FDA decision dates, and potential market size for each candidate. The R&D expense disclosures show investment priorities across therapeutic areas, while risk factor sections outline regulatory, competitive, and patent expiration challenges facing each product franchise.
Form 4 insider transaction filings track when AbbVie executives and directors buy or sell company shares. These transactions can signal management confidence in upcoming catalysts such as FDA approvals, clinical trial results, or strategic acquisitions. Our platform flags significant Form 4 activity automatically.
AbbVie 8-K filings announce material events including acquisition completions, major licensing agreements, FDA decisions, and leadership changes. For a company of AbbVie size and acquisition activity, 8-K filings often contain market-moving information about pipeline expansion and strategic direction.
The DEF 14A proxy statement reveals executive compensation structures, performance metrics tied to bonuses, and board composition details. For institutional investors, these disclosures inform governance assessments and say-on-pay voting decisions.
Our AI summaries translate complex pharmaceutical disclosures into clear explanations, highlighting revenue trends, pipeline updates, and segment performance without requiring hours of document review. Access real-time EDGAR updates for all AbbVie regulatory filings in one location.
AbbVie Inc. updated its earnings outlook to reflect a large research and development charge in the fourth quarter of 2025. The company expects acquired in-process R&D and milestones expense of
Including this fourth quarter expense, AbbVie now expects its full-year 2025 adjusted diluted EPS to be in the range of
AbbVie Inc. director Robert J. Alpern reported a routine compensation-related transaction. On 12/31/2025, he acquired 34 stock equivalent units tied to AbbVie common stock at $228.49 per unit, bringing his total holdings of these derivative securities to 10,257 stock equivalent units.
According to the disclosure, these units represent director fees credited to stock equivalent unit accounts under grantor trusts established at Abbott Laboratories and AbbVie. The units are paid out in cash, generally at age 65 or upon retirement from each company’s board, and earn the same return as if the fees were invested in AbbVie stock. The reported balance also reflects units acquired through a dividend reinvestment feature.
AbbVie Inc. director equity filing: A Form 4 reports that a director of AbbVie received 68 stock equivalent units on 12/31/2025 at a reference value of $228.49 per unit. These units are credited as director fees into a stock equivalent unit account in a grantor trust and are generally paid in cash at about age 65 or upon retirement from the board. After this transaction, the director beneficially owns 707 stock equivalent units, which are designed to earn the same return as if the fees were invested directly in AbbVie common stock, including through a dividend reinvestment feature.
AbbVie Inc. director Edward J. Rapp reported an acquisition of stock equivalent units tied to AbbVie stock. On 12/31/2025, 147 stock equivalent units were credited at a price of $228.49 per unit, bringing his total directly held derivative securities reported on this form to 28,498 stock equivalent units.
The units represent director fees credited to a stock equivalent unit account under a grantor trust established by the director and are paid in cash generally at age 65 or upon retirement from the board. These stock equivalent units earn the same return as if the fees were invested in AbbVie stock, and the reported balance includes units acquired through a dividend reinvestment feature.
AbbVie Inc. reported Q3 2025 results. Net revenues were $15,776 million, up from $14,460 million a year ago, while operating earnings fell to $1,904 million from $3,831 million as the company recorded significant charges. Net earnings were $186 million and diluted EPS was $0.10.
Results reflect acquired IPR&D and milestones expense of $2,680 million in the quarter and intangible asset impairments of $847 million in cost of products sold tied to Resonic and Durysta. Interest expense, net, was $667 million. For the nine months ended September 30, 2025, net revenues were $44,542 million and net earnings were $2,410 million; operating cash flow was $13,812 million.
AbbVie completed or announced portfolio moves: Capstan Therapeutics (cash consideration of $2.1 billion; $1.9 billion recognized in IPR&D), Ichnos Glenmark ISB-2001 license (upfront $700 million), ADARx options (upfront $335 million), Gubra license (upfront $350 million), Nimble Therapeutics acquisition (aggregate $288 million). Subsequent to quarter end, AbbVie acquired Gilgamesh Pharmaceuticals for approximately $900 million upfront. Total equity was a deficit of $2,599 million as of September 30, 2025.
AbbVie Inc. (ABBV) filed an 8-K announcing Q3 2025 results. The company issued a press release for the third quarter ended September 30, 2025, and furnished it with this report.
The press release is included as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition). No financial figures are detailed in this report itself.
Susan E. Quaggin, an AbbVie Inc. (ABBV) director, had 67 stock equivalent units credited to her account on 09/30/2025 at a unit value of $231.54. The filing shows these units are held in a grantor trust and are paid in cash generally at age 65 or upon retirement from the board; they earn returns as if invested in AbbVie stock. The report indicates a post-transaction beneficial ownership balance of 634 shares (including units acquired through a dividend reinvestment feature).
Robert J. Alpern, an AbbVie director, reported a Form 4 disclosing a non‑derivative acquisition on 09/30/2025 of 33 stock equivalent units credited at a per‑unit value of $231.54. The filing states these units are director fees credited to grantor trust accounts established by Abbott Laboratories and AbbVie and that AbbVie account units are payable in cash generally at age 65 or upon retirement from AbbVie’s board. The report shows a total beneficial ownership balance of 10,151 stock equivalent units (including amounts from dividend reinvestment). The Form 4 was signed by an attorney‑in‑fact on 10/02/2025.
FAQ
What is the current stock price of Abbvie (ABBV)?
What is the market cap of Abbvie (ABBV)?
